A retrospective, single-center, case-control trial of alemtuzumab based conditioning regimen instead of anti-thymocyte globulin in patient undergoing allogeneic stem cell transplantation

Trial Profile

A retrospective, single-center, case-control trial of alemtuzumab based conditioning regimen instead of anti-thymocyte globulin in patient undergoing allogeneic stem cell transplantation

Completed
Phase of Trial: Phase II

Latest Information Update: 16 Oct 2016

At a glance

  • Drugs Alemtuzumab (Primary) ; Antithymocyte globulin
  • Indications Transplant rejection
  • Focus Therapeutic Use
  • Most Recent Events

    • 16 Oct 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top